Critics Dismiss Latest Trump Pharma Deals as Obscure Distractions

The new agreements involve companies including Alcon, Astellas Pharma, and Teva Pharmaceuticals, yet critics remain unmoved. Peter Maybarduk of Public Citizen described the administration’s approach as a collection of secret, unenforceable deals that lack transparency. He noted that despite the high volume of announcements, there is no evidence that companies have actually launched new drugs at the promised "most favored nation" price points.

Public Citizen plans to file a Freedom of Information Act request to force the release of these documents, echoing frustrations expressed by Senator Elizabeth Warren regarding Health and Human Services Secretary Robert F. Kennedy Jr.'s refusal to make the initial 17 agreements public. Independent analysts suggest that many of these commitments are tied to temporary immunity from drug import tariffs rather than genuine price reform. Meanwhile, advocates for systemic change argue that true relief for patients requires enforceable measures and international reference pricing, rather than the voluntary, secret arrangements currently favored by the administration.